Corvus Pharmaceuticals (CRVS) IPO Opens Flat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall Street ends down as expectations of Hormuz deal fade
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Nvidia and Wall Street giants plan $500B AI funding deal, FT reports
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil climbs 5% as Iran, US both demand compensation and Hormuz hopes fade
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
Corvus Announces Pricing of Initial Public Offering
March 22, 2016 6:05 PM EDTBURLINGAME, Calif., March 22, 2016 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today announced the pricing of its initial public offering of 4,700,000 shares of its common stock at an initial public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 705,000 shares of common stock at the initial public offering price, before underwriting discounts and... More
